Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
Open Access
- 31 August 2006
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (9) , 2784-2792
- https://doi.org/10.1002/art.22052
Abstract
Objective Measurement of physical function at one point in time cannot distinguish impairment caused by the active disease process from chronic irreversible impairment. We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function. Methods We performed a secondary analysis of data from 6 contemporary clinical trials of RA (2,763 patients). Patients in whom remission was achieved in the trials, based on a simplified disease activity index, were identified. In an individual patient, HAQ scores at trial entry represented both reversible and irreversible impairments, while HAQ scores at the time of RA remission represented the mostly irreversible component, and the difference between these corresponded to the component related to disease activity. We tested the concept that the HAQ has a reversible and an irreversible component by associating the HAQ score during remission with 2 measures associated with the degree of accrued damage: duration of RA and radiographic severity. Results Among patients in whom clinical remission was achieved (n = 295), average HAQ scores despite clinical remission increased progressively with the duration of RA, from 0.19 (P < 0.001). The reversibility of HAQ scores decreased with the duration of RA (median 100%, 83.3%, 81.9%, and 66.7%, respectively; P < 0.001). Findings were similar in patients subgrouped by quartile of radiographic scores. Conclusion Differences in the sources of functional limitations should be considered in the interpretation of functional measures, and in their use for prediction and in cost analyses.Keywords
This publication has 28 references indexed in Scilit:
- The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a surveyRheumatology, 2006
- Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trialsAnnals of the Rheumatic Diseases, 2006
- Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity statesArthritis & Rheumatism, 2005
- Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in SwedenAnnals of the Rheumatic Diseases, 2005
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Patients with rheumatoid arthritis in clinical careAnnals of the Rheumatic Diseases, 2004
- Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UKRheumatology, 2003
- Modeling the progression of rheumatoid arthritis: A two‐country model to estimate costs and consequences of rheumatoid arthritisArthritis & Rheumatism, 2002
- How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?Arthritis & Rheumatism, 1985
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980